CELLINK signs collaboration agreement with CTIBIOTECH for Bioprinting of patient-specific cancer tumors
CTIBIOTECH are leading a new path towards personalized cancer therapies through utilization of CELLINK’s technology platform. By taking a small piece of a patient’s tumor, multiplying the cells, and then bioprinting the patient’s tumor in the laboratory, researchers can discover, understand and find the exact treatment best for the specific cancer. CTIBIOTECH uses 3D bioprinting technologies, including the CELLINK BIO X 3D printing system and bioinks, to advance models and lead the way forward for treating cancer in the future. Professor Colin McGuckin (Founder, CTIBIOTECH) “We are proud